Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from William Blair

Why Is Cardiff Oncology Stock Trading Lower After Colorectal Cancer Data?

As advancements in cancer treatment continue to evolve, the pursuit of more effective therapies for metastatic colorectal cancer remains a critical focus in the pharmaceutical industry. Cardiff Oncology, Inc. (NASDAQ:CRDF) on Tuesday released data from the ongoing CRDF-004 Phase 2 clinical trial evaluating onvansertib in combination with standard-of-care (SoC) in…

Benzinga

AI-Focused Waystar, Iodine Deal Wins Praise For Margin Upside

Waystar Holding (NASDAQ:WAY) on Wednesday agreed to acquire Iodine Software from shareholders led by Advent International, a private equity firm, for a total of $1.25 billion.

Benzinga

Quest Diagnostics Raises Outlook, But Warns Of Tariff And Medicare Act Risks

Quest Diagnostics Inc. (NYSE:DGX) delivered a robust second quarter in 2025, exceeding analyst expectations with strong sales and earnings growth, prompting an upward revision to its full-year guidance.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Sarepta's Setback Deepens With Another Gene Therapy Fatality

Sarepta Therapeutics (NASDAQ:SRPT) shares plummeted on Friday following reports of a third patient death linked to its gene therapy pipeline this year, further clouding investor confidence despite the company’s recent efforts to provide clarity on its restructuring and FDA label plans.

Benzinga

Tesla’s Q2 Earnings Will Likely Focus on Politics and Robotaxis, But Investors Should Really Watch for These 5 Things

Tesla will release its Q2 2025 earnings next week. While AI and CEO Elon Musk’s politics might take center stage, there are some other pressing issues that the company should address.

Barchart

Medtronic Stock Is Climbing Friday: What's Going On?

On Wednesday, the Centers for Medicare Medicaid Services (CMS) proposed a significant step toward broader adoption of renal denervation (RDN) by offering coverage for both radiofrequency (rfRDN) and ultrasound (uRDN) technologies for uncontrolled hypertension. This coverage would be granted under a Coverage with Evidence Development (CED) framework, requiring treatment within…

Benzinga

Elon Musk Launches the America Party. How Should You Play Tesla Stock Here?

Tesla stock lost nearly 7% Monday after Elon Musk announced plans of launching the “America Party.” William Blair downgraded TSLA shares.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Can Oklo Stock Hit $75 in 2025?

Wedbush analysts have an ambitious price target of $75 on Oklo’s stock.

Barchart

From In-N-Out to McDonald’s: The restaurant chains with the highest and lowest employee satisfaction scores revealed

91 percent of In-N-Out employees said they’d recommend their jobs to a friend

The Independent UK

Elon Musk’s ‘KILL the BILL’ Sends Tesla Shares Down. Is It Time to Sell TSLA Stock Here?

Tesla shares crater as President Donald Trump says he’s disappointed in Elon Musk. A William Blair analyst remains bullish on TSLA stock.

Barchart

Analysts Are Pounding the Table on This ‘Pioneer’ Nuclear Energy Stock

This nuclear stock has received a positive analyst rating after a favorable announcement from the government.

Barchart

This Analyst Is Calling for ‘Near Term’ Upside in Palantir Stock Despite the Tariffs Selloff

A William Blair analyst says Palantir stock is positioned for near-term gains. Should you buy the recent dip in PLTR shares then?

Barchart

The Bloodshed in Palantir Stock Is So Bad This Analyst Just Upgraded the Stock

A continued rout in Palantir stock made one of its long-time skeptics change his stance on the big data analytics firm on Wednesday.

Barchart

3 Tech Stocks to Buy for Steady Growth in 2025

These companies all have huge growth potential in 2025 thanks to innovation and transformation in industries like data centers and artificial intelligence.

Barchart

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Regulatory Setback For Applied Therapeutics' Lead Program, FDA Highlights Deficiencies In Clinical Application

FDA rejected Applied Therapeutics' Govorestat for galactosemia, citing NDA deficiencies. The company plans discussions for resubmission or appeal.

Fortune

Chipotle's new CEO gets approving nod from analysts

Boatwright is likely to look to new CFO Adam Rymer as a strategic partner.

Kiplinger

Viking Therapeutics Stock Swings Wildly After Weight-Loss Drug Data

Viking Therapeutics stock is volatile Monday after the pharma company released positive data for its weight-loss drug. Here's what you need to know.

Barchart

1 AI Growth Stock to Grab While It's Under $100

This AI stock is currently trading below $100 following a pullback, which could be a perfect window for investors to snag this growth stock now.

Get all your
news in one place.

100’s of premium titles.
One news app.

Kiplinger

Moderna Stock Plunges as Vaccine Maker Slashes R&D Budget: What to Know

Moderna stock is plunging Thursday after the COVID-19 vaccine maker announced plans to drastically cut its R&D spending to focus on new product approvals.

Barchart

Is Tesla Stock a Buy for Energy Storage Upside?

This article explores whether Tesla stock is a good investment for those looking to capitalize on the potential growth of its energy storage business, which is increasingly seen as a significant driver of future upside.

Kiplinger

Chewy Stock Soars on Big Profit Beat. Is It Time to Buy?

Chewy is red-hot Wednesday after the pet products retailer posted impressive Q2 earnings. Here's what Wall Street has to say about the stock.

Kiplinger

Visa Is the Worst Dow Stock Wednesday. Here's Why

Visa stock is down sharply Wednesday after the credit card company came up short of revenue expectations for its fiscal Q3.

Kiplinger

Dave & Buster's Stock Tanks on Earnings Miss: What To Know

Dave & Buster's stock is plunging after the entertainment and restaurant chain reported weaker-than-expected Q1 earnings. Here's what you need to know.

Barchart

1 Breakout Small-Cap Agricultural Stock to Scoop Up Now

With a growing population fueling demand for agricultural goods, it might be smart to consider investing in the small-cap agricultural stock Vital Farms now.

Barchart

Up 931% in One Year, Is Carvana Stock Overvalued?

Investor interest in Carvana stock continued to grow after the company reported its first-ever annual profit, leading to a 931% price spike over the past year. Is a pullback ahead for the stock?

1 2 3

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.